Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 205

Related Citations for PubMed (Select 8070610)

1.

Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.

Nielsen FS, Rossing P, Gall MA, Skøtt P, Smidt UM, Parving HH.

Diabetes. 1994 Sep;43(9):1108-13.

PMID:
8070610
2.

Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.

Nielsen FS, Rossing P, Gall MA, Skøtt P, Smidt UM, Parving HH.

Diabetes. 1997 Jul;46(7):1182-8.

PMID:
9200654
3.
4.

Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy.

Nielsen FS, Rossing P, Gall MA, Smidt UM, Chen JW, Sato A, Parving HH.

Scand J Clin Lab Invest. 1997 Aug;57(5):427-34.

PMID:
9279969
5.

Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.

Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH.

Diabetes Care. 2000 Dec;23(12):1725-30.

6.

Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy.

Tarnow L, Sato A, Ali S, Rossing P, Nielsen FS, Parving HH.

Diabetes Care. 1999 Mar;22(3):491-4.

7.

Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.

Brocco E, Velussi M, Cernigoi AM, Abaterusso C, Bruseghin M, Carraro A, Sambataro M, Piarulli F, Sfriso A, Nosadini R.

J Nephrol. 2001 Nov-Dec;14(6):461-71.

PMID:
11783602
8.

Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.

Salako BL, Finomo FO, Kadiri S, Arije A, Olatosin AO.

Afr J Med Med Sci. 2002 Mar;31(1):53-7.

PMID:
12518931
9.
10.

Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM.

Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Villa GM, Nosadini R.

Diabetes Care. 1998 Jan;21(1):104-10.

PMID:
9538979
11.

ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension.

Himmelmann A, Hansson L, Hansson BG, Hedstrand H, Skogström K, Ohrvik J, Furängen A.

Blood Press. 1995 Mar;4(2):85-90.

PMID:
7599759
12.

Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy.

Christensen PK, Rossing P, Nielsen FS, Parving HH.

Diabet Med. 1999 May;16(5):388-94.

PMID:
10342338
13.

Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy.

Hansen HP, Nielsen FS, Rossing P, Jacobsen P, Jensen BR, Parving HH.

Kidney Int Suppl. 1997 Dec;63:S49-53.

PMID:
9407421
14.
16.

Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine.

Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH.

J Hum Hypertens. 1996 Mar;10(3):185-92.

PMID:
8733038
17.

Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy.

Sørensen VB, Rossing P, Tarnow L, Parving H, Nørgaard T, Kastrup J.

Clin Sci (Lond). 1998 Dec;95(6):709-17.

18.

Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients.

Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R.

Diabetes. 1996 Feb;45(2):216-22.

PMID:
8549868
19.

Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy.

Hansen HP, Christensen PK, Tauber-Lassen E, Klausen A, Jensen BR, Parving HH.

Kidney Int. 1999 Feb;55(2):621-8.

20.

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.

Arch Intern Med. 2005 Apr 25;165(8):936-46.

PMID:
15851647
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk